Evidence map›Paper›PMID 38482586›Full record

ArticleRenal failure2024

Analysis of chronic kidney disease epidemiology in Kazakhstan using nationwide data for 2014-2020 and forecasting future trends of prevalence and mortality for 2030.

Gulnur Zhakhina, Kamilla Mussina, Sauran Yerdessov, Arnur Gusmanov, Yesbolat Sakko, Valdemir Kim, Dmitriy Syssoyev, Meruyert Madikenova, Ainur Assan, Zhanat Kuanshaliyeva and 4 more

Open access · goldAbstract read
In one paragraph

Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Gulnur ZhakhinaDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Kamilla MussinaDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Sauran YerdessovDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Arnur GusmanovDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Yesbolat SakkoDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Valdemir KimDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Dmitriy SyssoyevDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Meruyert MadikenovaDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Ainur AssanDepartment of Medicine, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkistan, Kazakhstan.
Zhanat KuanshaliyevaClinical Academic Department of Internal Medicine, CF "University Medical Center", Astana, Kazakhstan.
Duman TurebekovDepartment of Internal Medicine and Nephrology, Astana Medical University, Astana, Kazakhstan.
Kuanysh YergaliyevDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Bolat BekishevDepartment of Extracorporeal Hemocorrection, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Abduzhappar GaipovDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Nazarbayev University · KZAstana Medical University · KZAhmet Yesevi University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to the Global Burden of Disease (GBD) study, chronic kidney disease (CKD) was prevalent in 697.5 million individuals worldwide in 2017. By 2040, it is anticipated that CKD will rank as the fifth most common cause of death. This study aims to examine the epidemiology of CKD in Kazakhstan and to project future trends in CKD prevalence and mortality by 2030. The retrospective analysis was performed on a database acquired from the Unified National Electronic Health System for 703,122 patients with CKD between 2014 and 2020. During the observation period, 444,404 women and 258,718 men were registered with CKD, 459,900 (66%) were Kazakhs and 47% were older than 50. The incidence rate notably decreased: 6365 people per million population (PMP) in 2014 and 4040 people PMP in 2020. The prevalence changed from 10,346 to 38,287 people PMP, and the mortality rate increased dramatically from 279 PMP to 916 PMP. Kazakhstan's central regions, Turkestan and Kyzylorda were identified as the most burdensome ones. The ARIMA model projected 1,504,694 expected prevalent cases in 2030. The predicted mortality climbed from 17,068 cases in 2020 to 37,305 deaths in 2030. By 2030, the prevalence and mortality of CKD will significantly increase, according to the predicted model. A thorough action plan with effective risk factor management, enhanced screening among risk populations, and prompt treatment are required to lessen the burden of disease in Kazakhstan.

Indexed as

Central Asian PeopleRenal Insufficiency, ChronicFemaleForecastingHumansIncidenceKazakhstanMaleMiddle AgedPrevalenceRetrospective StudiesChronic kidney diseasemortality forecastingnationwide administrative dataprevalence forecastingrisk factorsurvival analysis

Identifiers

PMID38482586
PMCPMC10946271
OpenAlexW4392817329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.